InfuSystem enters its third-quarter report with an unusual gap between what management says and what Wall Street believes. The company has kept its full-year revenue outlook at $152.05 million to $154.92 million, yet the consensus estimate for 2026 sits at just $145.70 million, comfortably below even the low end of that range. Meanwhile the stock has climbed more than 39% since the last report. Results due before the open on November 3 should show whether the market's enthusiasm or the analysts' caution is closer to the mark.
The arithmetic explains the skepticism. InfuSystem booked $33.7 million in the first quarter and a record $36.9 million in the second, about $70.6 million combined. Hitting the bottom of guidance would require the second half to average roughly $40.7 million a quarter, a sizable step up from a quarter that was already a company high. The Street's number implies something closer to $37.5 million a quarter, which is a more modest improvement on the $36.5 million posted in the year-ago third quarter. A quarterly revenue figure that lands near $38 million or better would make management's range look credible; one stuck near the second quarter's level would suggest the full-year target is at risk. Earnings consensus data is not usable here, so the revenue trajectory and margins carry more weight than usual. For reference, the company earned $0.11 a share in the year-ago quarter and $0.15 last quarter.
The second-quarter call laid out why management believes the back half can carry the load. Pro forma growth re-accelerated to 7.5% from 1.7% in the first quarter, oncology topped $20 million for the first time with 6.4% growth after several quarters stuck in the 2% to 4% range, and management described that pace as sustainable thanks to new hospital wins and better collections. Wound care and compression revenue more than doubled again, and a second compression device manufacturer has joined the platform. The cleanest validation this quarter would be oncology holding near a 6% clip while compression keeps adding roughly $2 million of year-over-year revenue. A slip back toward low-single-digit oncology growth would undercut the claim that the second quarter marked a genuine inflection rather than a good stretch.
Margins are the other half of the story. Adjusted EBITDA margin rebounded to 23.4% from a seasonally weak 18.9%, and management signaled more upside than downside within its 22% to 25% full-year range. Device Solutions gross margin jumped to 50.2% as the restructured GE contract traded revenue for profit, and ERP spending has fallen to about $300,000 a quarter. The countervailing pressure is in patient services, where gross margin dipped to 61.8% as lower-margin wound care grew faster and pump maintenance costs rose. If faster compression growth keeps eroding that margin, the revenue mix that drives the top line could quietly cap profitability. Readers should also look for any early effect from the CMS prior-authorization rule on compression devices that took effect in April, which management said had not yet bitten.
Sentiment has warmed considerably, with the reading improving to about 20% bearish from roughly 68% bearish before the last report. The stock, at $14.13, sits well above its 200-day moving average of $10.24 and within about 2% of its post-earnings high of $14.41, effectively testing a breakout after trading between $8.04 and $10.32 the prior quarter. That move means the easy re-rating may already be done, and the bar has risen accordingly.
The central question is whether InfuSystem can show the start of the second-half acceleration its guidance requires. Sustained oncology momentum, continued compression growth and EBITDA margin holding in the mid-20s would vindicate management and pressure analysts to close the gap toward the company's range. Anything less would suggest the Street's discount was justified, and a stock priced near its highs would have little cushion.